Twist Bioscience stock has delivered a very strong 261.2% return over the past 3 years, yet the broader valuation checks point to a company that currently appears expensive rather than obviously cheap. That tension between a powerful share price run and a low value score is what investors now have to weigh.
- Twist Bioscience's 261.2% return over 3 years highlights how much optimism is already reflected in the share price.
- Expectations around the company turning its science into durable revenue and cash flow can support the current valuation, but execution risks and future funding needs may limit how much more investors are willing to pay.
- On Simply Wall St's broader checklist, Twist Bioscience scores 2 out of 6 on valuation, which suggests the stock is not a clear bargain at today's levels.
The issue now is whether Twist Bioscience's current share price already reflects most of the upside implied by its long term potential, or if there is still room for investors to be rewarded from here.
Does Twist Bioscience Look Pricey on Sales?
P/S is often a better fit for Twist Bioscience because the company is still working toward consistent profitability, so revenue offers a clearer anchor than earnings. Twist Bioscience currently trades on a P/S of about 13.7x, compared with an estimated 10.8x for the wider biotechs industry and around 7.2x across closer peers, so the stock sits on a clear premium to both groups.
Simply Wall St's fair P/S ratio for Twist Bioscience is calculated at about 6.0x, which reflects what investors might expect to pay given its industry, size and risk profile. That is less than half of the current 13.7x multiple, indicating that a lot of optimism around future revenue already appears to be factored into the price and leaving the stock looking overvalued on this measure.
On the P/S multiple, Twist Bioscience stock currently screens as overvalued compared with both peers and the modelled fair ratio.
See what the numbers say about this price — find out in our valuation breakdown.
The Twist Bioscience Narrative: What Would Justify Today's Price?
Simply Wall St Narratives pick up where Twist Bioscience's valuation puzzle leaves off. They spell out which assumptions about future growth, margins and earnings would need to hold for the stock to be worth meaningfully more or less than it is today. Each Narrative links a fair value estimate to a specific storyline about Twist Bioscience's potential catalysts and risks, so you can see over time which version of events is closest to reality on the Community page.
Community views on Twist Bioscience sit at opposite ends, with one camp seeing a multi year opportunity and the other warning expectations may already be stretched.
Bull case: 25% undervalued
"Intensifying adoption of AI-driven drug discovery, coupled with swelling investment in next-gen biomanufacturing, is creating new high-value use cases for customized DNA and antibody libraries…"
Read the full Bull Case to see why Twist Bioscience could be undervalued
Bear case: 27% overvalued
"Twist Bioscience remains unprofitable, with an expected adjusted EBITDA loss of $45 million to $47 million for fiscal 2025, and only a goal, not a guarantee, to achieve breakeven in 2026…"
Read the full Bear Case to see why Twist Bioscience could be overvalued
Do you think there's more to the story for Twist Bioscience? Head over to our Community to see what others are saying!
The Bottom Line
Twist Bioscience currently screens as overvalued on market multiples, with a clear premium to both its industry and closer peers. That setup means you are paying up today for the prospect that the company converts its scientific platform into stronger revenue and, over time, better cash flow. The crux of the bull versus bear debate is whether Twist Bioscience can execute on that path quickly and reliably enough to justify holding that premium, or whether expectations eventually need to cool and the multiple resets closer to sector norms.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com